These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33562701)

  • 21. Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat.
    Stenman E; Jamali R; Henriksson M; Maddahi A; Edvinsson L
    Eur J Pharmacol; 2007 Sep; 570(1-3):142-8. PubMed ID: 17597600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of combined treatment with curcumin and candesartan on ischemic brain damage in mice.
    Awad AS
    J Stroke Cerebrovasc Dis; 2011 Nov; 20(6):541-8. PubMed ID: 20719539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats.
    Panahpour H; Nekooeian AA; Dehghani GA
    Iran Biomed J; 2014; 18(4):232-8. PubMed ID: 25326022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
    Riegger GA; Bouzo H; Petr P; Münz J; Spacek R; Pethig H; von Behren V; George M; Arens H
    Circulation; 1999 Nov; 100(22):2224-30. PubMed ID: 10577995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
    Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
    Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility of treating prehypertension with an angiotensin-receptor blocker.
    Julius S; Nesbitt SD; Egan BM; Weber MA; Michelson EL; Kaciroti N; Black HR; Grimm RH; Messerli FH; Oparil S; Schork MA;
    N Engl J Med; 2006 Apr; 354(16):1685-97. PubMed ID: 16537662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma.
    Yang H; Hirooka K; Fukuda K; Shiraga F
    Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5800-4. PubMed ID: 19608537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibiting angiotensin receptors in the brain: possible therapeutic implications.
    Unger T
    Curr Med Res Opin; 2003; 19(5):449-51. PubMed ID: 13678486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
    Omura-Matsuoka E; Yagita Y; Sasaki T; Terasaki Y; Oyama N; Sugiyama Y; Okazaki S; Sakoda S; Kitagawa K
    Hypertens Res; 2009 Jul; 32(7):548-53. PubMed ID: 19424281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury.
    Kusaka I; Kusaka G; Zhou C; Ishikawa M; Nanda A; Granger DN; Zhang JH; Tang J
    Am J Physiol Heart Circ Physiol; 2004 Jun; 286(6):H2442-51. PubMed ID: 15148062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - A randomized double- blind pre-clinical study.
    Ahmed HA; Ishrat T; Pillai B; Bunting KM; Patel A; Vazdarjanova A; Waller JL; Arbab AS; Ergul A; Fagan SC
    Behav Brain Res; 2018 Jul; 346():29-40. PubMed ID: 29229547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.
    Schmerbach K; Schefe JH; Krikov M; Müller S; Villringer A; Kintscher U; Unger T; Thoene-Reineke C
    Brain Res; 2008 May; 1208():225-33. PubMed ID: 18378216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G; Fuchs W
    Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist.
    Ito T; Yamakawa H; Bregonzio C; Terrón JA; Falcón-Neri A; Saavedra JM
    Stroke; 2002 Sep; 33(9):2297-303. PubMed ID: 12215602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
    Engelhorn T; Goerike S; Doerfler A; Okorn C; Forsting M; Heusch G; Schulz R
    J Cereb Blood Flow Metab; 2004 Apr; 24(4):467-74. PubMed ID: 15087716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion.
    Ozacmak VH; Sayan H; Cetin A; Akyildiz-Igdem A
    Neurochem Res; 2007 Aug; 32(8):1314-21. PubMed ID: 17401654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.
    Shimizu M; Wang QD; Sjöquist PO; Rydén L
    J Cardiovasc Pharmacol; 1999 Oct; 34(4):512-7. PubMed ID: 10511125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An angiotensin II type 1 receptor blocker, candesartan, increases myocardial apoptosis in rats with acute ischemia-reperfusion.
    Chen M; Hamada M; Hiasa G; Suzuki M; Ikeda S; Hiwada K
    Hypertens Res; 2001 May; 24(3):323-9. PubMed ID: 11409658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.